Heise, Tim
Andersen, Grit
Pratt, Edward J. http://orcid.org/0000-0003-4449-6231
Leohr, Jennifer
Fukuda, Tsuyoshi
Wang, Qianqian
Kazda, Christof
Bue-Valleskey, Juliana M.
Bergenstal, Richard M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes
https://doi.org/10.1007/s13300-024-01605-7
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 25 March 2024
Accepted: 8 May 2024
First Online: 22 June 2024
Declarations
:
: Edward J. Pratt, Jennifer Leohr, Tsuyoshi Fukuda, Qianqian Wang, Christof Kazda, and Juliana M. Bue-Valleskey are employees and shareholders of Eli Lilly and Company. Tim Heise is shareholder of Profil, a private research institute that received research grants from Adocia, Astra Zeneca, Altimmune, Biocon, Bioton, Civica Foundation, Crinetics Pharmaceuticals, Eli Lilly and Company, Enyo Pharma, Gan & Lee Pharmaceuticals, Genova, Nanexa AB, Novo Nordisk, SamChunDang Pharm. Co., Sanofi, and Zealand Pharma. Tim Heise received speaker honoraria from Eli Lilly and is a consultant to Gan & Lee Pharmaceuticals. Grit Andersen has no conflicts of interest to declare. Richard M. Bergenstal has received research support from, has acted as a consultant for, or has been on the scientific advisory board for Abbott Diabetes Care, ARKRAY, Ascensia, Bigfoot Biomedical, CeQur, Dexcom, Eli Lilly, Embecta, Hygieia, Insulet, MannKind, Medtronic, Novo Nordisk, Onduo, Roche Diabetes Care, Tandem Diabetes Care, Sanofi, United Healthcare, Vertex Pharmaceuticals, and Zealand Pharma.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, and with Good Clinical Practice guidelines. The protocol was approved by the Ethics Committee of the North Rhine Medical Association (protocol reference number: 202051). Informed consent was obtained from all individual participants included in the study.